Home | Register | Login | Inquiries | Alerts | Sitemap |  

Advanced Search
JKM > Volume 40(1); 2019 > Article
Kim, Jo, Kang, Choi, Song, Sul, and Leem: Proposal of Evidence-based East-West Integrative Medicine Manual for Vascular Dementia



This study was made by Chung Yeon Korean Medicine Hospital in order to perform appropriate East-West integrative medicine. The purpose of this manual is to support decision-making and communication in the implementation of the East-West cooperative treatment of vascular dementia.


In order to carry out this study, it is based on search terms such as ‘vascular dementia’, ‘acupuncture’, ‘herbal medicine’, ‘integrative medicine’, ‘chinese traditional medicine’, and ‘cognitive function’ in databases such as MEDLINE, EMBASE, OASIS and CNKI We collected references.
The drafting proceeded with the collaboration of two specialists of the Korean medicine, and the disagreement on the basis of the quotation was determined through a two person agreement. After, The draft was reviewed by a western medical doctor(rehabilitation specialist). Then, The opinions of the entire medical staff of the committee were reflected in the draft and finalized the agreement.


Through this study, manuals for diagnosis, treatment, and other considerations in the process of applying East-West integrative medicine to vascular dementia were derived.


This study has significance in that it provides manual information about the decision structure, treatment contents, role distribution, etc. of East-West integrative medicine within the medical institution that conducts the vascular dementia consultation. In order for this study to function as a generalized medical guideline, it is necessary to improve the research methodology and carry out professional consensus procedures.

Fig. 1
Clinical Pathway of East-West Integrative Medicine for Vascular Dementia
Table 1
NINDS-AIREN Criteria for the Diagnosis of Probable Vascular Dementia
The criteria for the clinical diagnosis of probable vascular dementia include all of the following
1. Dementia The diagnosis of dementia should be based on a decline in cognitive function from a prior baseline and a deficit in performance in 2 or more cognitive domains (orientation, attention, language, visuospatial functions, executive functions, motor control, and praxis) that are of sufficient severity to affect the subject’s activities of daily living.
Those having disturbances of consciousness, delirium, psychosis, severe aphasia, or major sensorimotor impairment precluding neuropsychological testing are excluded.
Also excluded are systemic disorders or other brain diseases (such as Alzheimer’s disease) that in and of themselves could account for deficits in memory and cognition.
2. Cerebrovascular disease Defined by the presence of focal signs on neurologic examination, such as hemiparesis, lower facial weakness, Babinski sign, sensory deficit, hemianopia, and dysarthria consistent with stroke (with or without history of stroke), and evidence of relevant CVD by brain imaging (CT or MRI)
3. A relationship between the above two disorders Manifested or inferred by the presence of one or more of the following: (a) onset of dementia within 3 months following a recognized stroke; (b) abrupt deterioration in cognitive functions; or fluctuating, stepwise progression of cognitive deficits.
Table 2
Characteristics of the Respondents
Subtypes Imaging and pathological change
Multi-infarct dementia (cortical vascular dementia) Multiple cortical infarct
Small vessel dementia (subcortical vascular dementia) Lacunes, extensive white matter lesions; pathologically, infarcts, demyelination, and gliosis
Strategic infarct dementia Infarct in strategic location (e.g. thalamus)
Hypoperfusion dementia Watershed infarcts, white matter lesions; pathologically, incompleted infarcts in white matter
Haemorrhagic dementia Haemorrhagic changes, may be associated with amyloid angiopathy
Hereditary vascular dementia (CADASIL) Multiple lacunes and white matter lesions, temporal lobe white matter affected
Alzheimer’s disease with cardiovascular disease Combination of vascular changes and atrophy, especially medial temporal lobe; pathologically, mixture of vascular and degenerative (plaque and tangle) pathology
Table 3
Role Table of East-West Integrative Medicine for Vascular Dementia
Korean medicine Western medicine
Diagnosis 1)history taking, physical examination, neurological examination, screening test (including MMSE)
2)evaluation for patients who screen positive (including CDR, GDS, KDSQ, ADL, HIS)
3)Imaging test consult for differential diagnosis
4)examination for pattern identification (including pulse diagnosis, abdominal palpation)
3)Imaging test for differential diagnosis
Treatment 1)acupuncture (including manual acupuncture, electroacupuncture, scalp acupuncture, pharmacopuncture), cupping (including dry cupping, wet cupping), moxibustion.
2)herbal medication (including decoction, capsule, pill, tablet, granule, powder, concentrate extract)
3)Korean medicine psychotherapy such as Yijeongbyunqi(移精變氣) therapy, family therapy etc.
1)cognitive training and cognitive rehabilitation
2)Cognitive-behavioural therapy
3)Oral medication, Injection treatment
Management 1)management and monitoring of coexistence risk factor (including stroke, hypertension, hyperlipidemia, diabetes mellitus, alcohol dependence, obesity)
2)education and adjustment of the patient’s lifestyle
3)patient carer consultation


1. O’Brien JT, Thomas A. Vascular dementia. Lancet. 2015; 386:10004. 1698–706.
crossref pmid

2. Rodríguez García PL, Rodríguez García D. Diagnosis of vascular cognitive impairment and its main categories. Neurologia. 2015; 30:4. 223–39.
crossref pmid

3. Kokmen E, Whisnant JP, O’Fallon WM, Chu CP, Beard CM. Dementia after ischemic stroke: a population-based study in Rochester, Minnesota (1960–1984). Neurology. 1996; 46:154–159.

4. Al-Qazzaz NK, Ali SH, Ahmad SA, Islam S, Mohamad K. Cognitive impairment and memory dysfunction after a stroke diagnosis: a post-stroke memory assessment. Neuropsychiatr Dis Treat. 2014; 10:1677–91.
crossref pmid pmc

5. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009; Nov. 8:11. 1006–18.
crossref pmid

6. Allan LM, Rowan EN, Firbank MJ, Thomas AJ, Parry SW, Polvikoski TM, et al. Long term incidence of dementia, predictors of mortality and pathological diagnosis in older stroke survivors. Brain. 2011; 134:Pt 12. 3716–27.
crossref pmid pmc

7. Xu QQ, Shan CS, Wang Y, Shi YH, Zhang QH, Zheng GQ. Chinese Herbal Medicine for Vascular Dementia: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials. J Alzheimers Dis. 2018; 62:1. 429–456.
crossref pmid

8. Wang S, Yang H, Zhang J, Zhang B, Liu T, Gan L, et al. Efficacy and safety assessment of acupuncture and nimodipine to treat mild cognitive impairment after cerebral infarction: a randomized controlled trial. BMC Complement Altern Med. 2016; 16:1. 361
crossref pmid pmc

9. Cao HX, Wang YY. Clinical practice guideline in traditional Chinese medicine for ischemic stroke. Evidence-based guideline of clinical practice in Chinese medicine. 1st ed. Beijing: China Press of Traditional Chinese Medicine;2011.

10. Lee GE, Jeon WK, Heo EJ, Yang HD, Kang HW. The study on the korean traditional medical treatment and system of collaborative practice between korean traditional medicin and western medicine for dementia: based on analysis of questionnaire survey in professional group. J of Oriental Neuropsychiatry. 2012; 23:4. 49–68.

11. Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993; 43:2. 250–60.
crossref pmid

12. van Straaten EC, Scheltens P, Knol DL, van Buchem MA, van Dijk EJ, Hofman PA, et al. Operational definitions for the NINDS-AIREN criteria for vascular dementia: an interobserver study. Stroke. 2003; 34:8. 1907–12.
crossref pmid

13. de Bruijn RF, Ikram MA. Cardiovascular risk factors and future risk of Alzheimer’s disease. BMC Med. 2014; Nov. 11. 12:130
crossref pmid pmc

14. Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF. Late-life depression and risk of vascular dementia and Alzheimer’s disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry. 2013; 202:5. 329–35.
crossref pmid pmc

15. O’Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, et al. Vascular cognitive impairment. Lancet Neurol. 2003; 2:2. 89–98.
crossref pmid

16. Stebbins GT, Nyenhuis DL, Wang C, Cox JL, Freels S, Bangen K, et al. Gray matter atrophy in patients with ischemic stroke with cognitive impairment. Stroke. 2008; 39:3. 785–93.
crossref pmid

17. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002; 288:12. 1475–83.
crossref pmid

18. Gupta M, Dasgupta A, Khwaja GA, Chowdhury D, Patidar Y, Batra A. Behavioural and psychological symptoms in poststroke vascular cognitive impairment. Behav Neurol. 2014; 2014:430128.
crossref pmid pmc

19. Tsoi KK, Chan JY, Hirai HW, Wong SY, Kwok TC. Cognitive Tests to Detect Dementia: A Systematic Review and Meta-analysis. JAMA Intern Med. 2015; 175:9. 1450–8.
crossref pmid

20. Reisberg B. Global measures: utility in defining and measuring treatment response in dementia. Int Psychogeriatr. 2007; 19:3. 421–56.

21. Choi SH, Na DL, Lee BH, Hahm D, Jeong JH, Yoon SJ; , et alDementia Research Group. Estimating the validity of the Korean version of Expanded Clinical Dementia Rating (CDR) scale. J Korean Neurol Assoc. 2001; 19:585–91.

22. Choi SH, Na DL, Lee BH, Halm D, Jeong JH, Jeong Y; , et alDementia Research Group. Ihe validity of the Korean version of Global Deterioration Scale. J Korean Neurol Assoc. 2002; 20:612–7.

23. Shin MH, Lee YM, Park JM, Kang CJ, Lee BD, Moon E, et al. A combination of the korean version of the mini-mental state examination and korean dementia screening questionnaire is a good screening tool for dementia in the elderly. Psychiatry Investig. 2011; 8:4. 348–53.
crossref pmid pmc

24. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53:4. 695–9.
crossref pmid

25. Kang SJ, Seong SH, Lee BH, Kwon JC, Na DL, Han SH; Korean dementia research group. The reliability and validity of the korean instrumental activities of daily living (K-IADL). J Korean Neurol Assoc. 2002; 20:1. 8–14.

26. Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, et al. Cerebral blood flow in dementia. Arch Neurol. 1975; 32:9. 632–7.
crossref pmid

27. Korean Dementia Association. Dementia A clinical Approach. 2nd ed.Academiya;2011. 424.

28. Price CC, Jefferson AL, Merino JG, Heilman KM, Libon DJ. Subcortical vascular dementia: integrating neuropsychological and neuroradiologic data. Neurology. 2005; 65:3. 376–82.
crossref pmid pmc

29. Fein G, Di Sclafani V, Tanabe J, Cardenas V, Weiner MW, Jagust WJ, et al. Hippocampal and cortical atrophy predict dementia in subcortical ischemic vascular disease. Neurology. 2000; 55:11. 1626–35.
crossref pmid pmc

30. Lee GE, Moon KS, Kim NK, Chung SY, Jung IC, Kang HW. Preliminary study to develop the Korean medical pathologic aging scale and korean medical pattern identification for dementia. J Korean Med. 2017; 38:3. 111–23.

31. Korean society of oriental neuropsychiatry. Korean Medicine Clinical Practice Guideline for Dementia. Seoul: Guideline center for Korean Medicine;2017.

32. Bahar-Fuchs A, Clare L, Woods B. Cognitive training and cognitive rehabilitation for persons with mild to moderate dementia of the Alzheimer’s or vascular type: a review. Alzheimers Res Ther. 2013; 5:4. 35
crossref pmid pmc

33. Spector A, Charlesworth G, King M, Lattimer M, Sadek S, Marston L, et al. Cognitive-behavioural therapy for anxiety in dementia: pilot randomised controlled trial. Br J Psychiatry. 2015; 206:6. 509–16.
crossref pmid

34. Kwon KJ, Kim MK, Lee EJ, Kim JN, Choi BR, Kim SY, et al. Effects of donepezil, an acetylcholinesterase inhibitor, on neurogenesis in a rat model of vascular dementia. J Neurol Sci. 2014; 347:1–2. 66–77.

35. Scapicchio PL. Revisiting choline alphoscerate profile: a new, perspective, role in dementia? Int J Neurosci. 2013; 123:7. 444–9.
crossref pmid

36. Alvarez-Sabín J, Román GC. Citicoline in vascular cognitive impairment and vascular dementia after stroke. Stroke. 2011; 42:1 Suppl. S40–3.
crossref pmid

37. Ye Y, Zhu W, Wang XR, Yang JW, Xiao LY, Liu Y, et al. Mechanisms of acupuncture on vascular dementia-A review of animal studies. Neurochem Int. 2017; Jul. 107:204–210.
crossref pmid

38. Ye Y, Li H, Yang JW, Wang XR, Shi GX, Yan CQ, et al. Acupuncture Attenuated Vascular Dementia-Induced Hippocampal Long-Term Potentiation Impairments via Activation of D1/D5 Receptors. Stroke. 2017; 48:4. 1044–1051.
crossref pmid

39. Li SK, Ding DM, Zhang ZL, Ma L, Huang HY, Wu XH. Effects of scalp acupuncture combined with auricular point sticking on cognitive behavior ability in patients with vascular dementia. Zhongguo Zhen Jiu. 2014; 34:5. 417–20.

40. Lee GE, Yang HD, Heo EJ, Jeon WK, Lyu YS, Kang HW. The current state of clinical studies on scalp acupuncture-treatment for dementia by search for China literature published from 2001 to 2011 in CAJ. J of Oriental Neuropsychiatry. 2012; 23:2. 13–32.

41. Liu Q, Wang XJ, Zhang ZC, Xue R, Li P, Li B. Neuroprotection against vascular dementia after acupuncture combined with donepezil hydrochloride: P300 event related potential. Neural Regen Res. 2016; 11:3. 460–4.
crossref pmid pmc

42. Shi GX, Li QQ, Yang BF, Liu Y, Guan LP, Wu MM, et al. Acupuncture for Vascular Dementia: A Pragmatic Randomized Clinical Trial. ScientificWorldJournal. 2015; 2015:161439.
crossref pmid pmc

43. Shi GX, Liu CZ, Guan W, Wang ZK, Wang L, Xiao C, et al. Effects of acupuncture on Chinese medicine syndromes of vascular dementia. Chin J Integr Med. 2014; 20:9. 661–6.
crossref pmid

44. Lee GE, Cheong MJ, Lee SI, Kim NK, Kim JW, Kang HW. Retrospective Analysis of Patients Suffering from Dementia or Mild Cognitive Impairment Treated by Collaboration between Western and Korean Medicine. J of Oriental Neuropsychiatry. 2018; 29:2. 111–9.

45. Harandi AA, Abolfazli R, Hatemian A, Ghragozlee K, Ghaffar-Pour M, Karimi M, et al. Safety and Efficacy of MLC601 in Iranian Patients after Stroke: A Double-Blind, Placebo-Controlled Clinical Trial. Stroke Res Treat. 2011; 2011:721613.
crossref pmid pmc

46. Heurteaux C, Gandin C, Borsotto M, Widmann C, Brau F, Lhuillier M, et al. Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo. Neuropharmacology. 2010; 58:7. 987–1001.
crossref pmid

47. Gandin C, Widmann C, Lazdunski M, Heurteaux C. MLC901 Favors Angiogenesis and Associated Recovery after Ischemic Stroke in Mice. Cerebrovasc Dis. 2016; 42:1–2. 139–54.
crossref pmid

48. Venketasubramanian N, Lee CF, Young SH, Tay SS, Umapathi T, Lao AY; , et alCHIMES-E Study Investigators. Prognostic Factors and Pattern of Long-Term Recovery with MLC601 (NeuroAiD™) in the Chinese Medicine NeuroAiD Efficacy on Stroke Recovery-Extension Study. Cerebrovasc Dis. 2017; 43:1–2. 36–42.

49. Tian J, Shi J, Wei M, Qin R, Ni J, Zhang X, et al. The efficacy and safety of Fufangdanshen tablets (Radix Salviae miltiorrhizae formula tablets) for mild to moderate vascular dementia: a study protocol for a randomized controlled trial. Trials. 2016; 17:1. 281
crossref pmid pmc

50. Protective effects of Compound Danshen Tablets on rat with vascular dementia caused by ischemia and reperfusion in middle cerebral artery. Pharmacol Clin Chin Materia Medica. 2015; 01:177–80.

51. Zhang XY, Qin X, Zhang YF, Lin J, Wang DQ, Qin RA, et al. Network pharmacology study on major active compounds of Fufang Danshen formula. Zhongguo Zhong Yao Za Zhi. 2011; 36:21. 2911–5.

52. China Association of Chinese Medicine, Chinese Medicine Standardization Branch of Chinese Medicine Standard Resaerch Center, Chinese Medicine Standard Research Center of China Academy of Chinese Medical Sciences. Guideline of Clinical Practice in Chinese Medicine-Vascuar Dementia(ZYYXH/T135- 2008). Bejing: China Press of Traditional Chinese Medicine;2015.

53. Shi J, Ni J, Lu T, Zhang X, Wei M, Li T, et al. Adding Chinese herbal medicine to conventional therapy brings cognitive benefits to patients with Alzheimer’s disease: a retrospective analysis. BMC Complement Altern Med. 2017; Dec. 17:1. 533
crossref pmid pmc

54. Keiko H, Hiromi R, Hisahiro Y, Atsuchi M, Takahiro S, Toshio O. Effect of kihito extract granules on cognitive function in patients with Alzheimer’s s-type dementia. Geriatr Gerontol Int. 2007; 7:3. 245–51.

55. Lee GE, Yang HD, Jeon WK, Kang Hw. A Study on the system of collaborative practice between korean traditional medicine and western medicine for dementia based on a case study. J of Oriental Neuropsychiatry. 2013; 24:3. 211–228.

56. Iadecola C. The pathobiology of vascular dementia. Neuron. 2013; Nov. 20. 80:4. 844–66.
crossref pmid pmc

57. Erkinjuntti T, Gauthier S. The concept of vascular cognitive impairment. Front Neurol Neurosci. 2009; 24:79–85.
crossref pmid

58. Lorius N, Locascio JJ, Rentz DM, Johnson KA, Sperling RA, Viswanathan A; , et alAlzheimer’s Disease Neuroimaging Initiative. Vascular disease and risk factors are associated with cognitive decline in the alzheimer disease spectrum. Alzheimer Dis Assoc Disord. 2015; 29:1. 18–25.
crossref pmid pmc

59. Dugger BN, Malek-Ahmadi M, Monsell SE, Kukull WA, Woodruff BK, Reiman EM, et al. A Cross-Sectional Analysis of Late-Life Cardiovascular Factors and Their Relation to Clinically Defined Neurodegenerative Diseases. Alzheimer Dis Assoc Disord. 2016; 30:3. 223–9.
crossref pmid pmc

60. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002; Apr. 13. 359:9314. 1283–90.
crossref pmid

61. Ballard C, Sauter M, Scheltens P, He Y, Barkhof F, van Straaten EC, et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr Med Res Opin. 2008; 24:9. 2561–74.
crossref pmid

62. Zeng L, Zou Y, Kong L, Wang N, Wang Q, Wang L, et al. Can Chinese Herbal Medicine Adjunctive Therapy Improve Outcomes of Senile Vascular Dementia? Systematic Review with Meta-analysis of Clinical Trials. Phytother Res. 2015; 29:12. 1843–57.
crossref pmid

PDF Links  PDF Links
Full text via DOI  Full text via DOI
PubReader  PubReader
Download Citation  Download Citation
Editorial office contact information
3F, #26-27 Gayang-dong, Gangseo-gu Seoul, 157-200 Seoul, Korea
The Society of Korean Medicine
Tel : +82-2-2658-3627   Fax : +82-2-2658-3631   E-mail : skom1953.journal@gmail.com
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Developed in M2PI